Adjuvant Therapy for High-Risk Gastrointestinal Stromal Tumors (GIST)

Risk Stratification

The National Comprehensive Cancer Network recommends that patients with high-risk GIST should receive 3 years of adjuvant imatinib therapy, provided their tumor does not have mutations likely to be resistant to therapy, such as PDGFRA exon 18 D842V mutation, with a high risk of recurrence associated with larger tumors, higher mitotic activity, non-gastric locations, and tumor rupture 1, 2
The European Society for Medical Oncology suggests that risk stratification for GIST recurrence is based on several key factors, including tumor size, with larger tumors (>5 cm) having higher risk of recurrence 3
The American Joint Committee on Cancer indicates that mitotic count is also a key factor, with higher mitotic activity (>5 mitoses per 5 mm²) indicating higher risk 3
The British Journal of Cancer states that tumor location is important, with non-gastric locations (especially rectal) carrying higher risk than gastric GISTs 1
The Annals of Oncology notes that tumor rupture before or during surgery significantly increases recurrence risk 1, 3

The American College of Pathologists recommends that mutational analysis is critical for adjuvant therapy decisions, with KIT exon 9 mutations potentially benefiting from higher imatinib dose (800 mg daily) 1, 3
The College of American Pathologists states that PDGFRA D842V mutation is resistant to imatinib, and adjuvant therapy should be avoided 1, 2
The National Institute of Health indicates that SDH-deficient GISTs have uncertain adjuvant therapy due to inaccurate risk stratification models 1

The National Comprehensive Cancer Network recommends that high-risk patients should receive 3 years of adjuvant imatinib, with intermediate-risk patients requiring shared decision-making, and low-risk patients not requiring adjuvant therapy 1, 2, 3
The European Society for Medical Oncology suggests that tumor rupture cases should receive at least 3 years of adjuvant imatinib, possibly lifelong, due to very high risk of peritoneal relapse 1, 4

The American Society of Clinical Oncology recommends that neoadjuvant therapy should be considered for primaries where immediate resection would be highly morbid, with optimal duration being 6-12 months based on maximal tumor response 1, 2
The Society of Surgical Oncology states that mutational analysis is mandatory prior to initiating neoadjuvant therapy 1

The National Comprehensive Cancer Network recommends that high-grade GIST patients should be followed up every 3-4 months for first 2-3 years, then every 6 months for years 4-5, then yearly up to 10 years 2
The European Society for Medical Oncology suggests that low-grade GIST patients should be followed up every 6 months for 5 years, then annually 2